Alkermes said the safety profile of its clinical-stage multiple sclerosis drug compares favorably to that of Biogen Idec's Tecfidera, citing the candidate's Phase I trial results on 104 patients.
Biogen Idec is aiming for slam-dunk sales of its multiple sclerosis powerhouse Tysabri, bringing on new sports talent to lead its MS campaign, "MS Inspiration," and to connect with patients with the disease.
With sales of its multiple sclerosis and hemophilia drugs growing, Biogen Idec is expanding operations at its manufacturing facility in Research Triangle Park, NC.
Biogen Idec has released a four-minute video via the Twitter sponsored feed that explains all of the manufacturing steps it goes through in making and purifying the treatment for hemophilia A.
Biogen Idec and its newly named in-house expert Olivier Danos have executed a research deal with the San Raffaele-Telethon Institute for Gene Therapy to develop what they believe promises to be a durable treatment for hemophilia.
The Google X lab that spawned smart contact lenses and self-driving cars is teaming up with Biogen Idec to unravel patient-to-patient variation in the progression of multiple sclerosis.
The Marketing Authorization Application for SB4, the Enbrel (etanercept) biosimilar candidate developed by Korean biopharmaceutical company Samsung Bioepis, has been validated and accepted for review by the European Medicines Agency. It will become the first Enbrel biosimilar subjected to regulatory review in the European Union.
Looking for some insights into the way that environment and biology influence the development of multiple sclerosis, Biogen Idec will team up with Google to sift through a mountain of data on the topic, according to a report from Bloomberg.
Back last summer the U.K.'s Convergence Pharmaceuticals, a spinout from GlaxoSmithKline, was feeling bullish about its prospects after it wrapped up a positive mid-stage study of its lead drug for neuropathic pain. But rather than take the risky step of mounting an IPO--still a tough prospect in the U.K.--Convergence instead opted to sell to Biogen Idec, which is using the acquisition to beef up its pipeline in the field.
Some of the cash will go toward creating a sequencing and analysis center at Columbia to support collaborative research.